BeOne Medicines (ONC) Operating Expenses (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Operating Expenses data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Operating Expenses rose 16.48% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 14.2% YoY) and the FY2025 annual result came in at $4.2 billion, up 11.71% from the prior year.
• Operating Expenses retreated to $1.1 billion in Q1 2026 per ONC's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $1.2 billion in Q4 2025 and bottomed at $562.2 million in Q4 2022.
• The 5-year median for Operating Expenses is $898.2 million (2024), against an average of $900.8 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 148.77%; it then declined 1.69% in 2023.
• Tracing ONC's Operating Expenses over 5 years: stood at $562.2 million in 2022, then jumped by 62.27% to $912.4 million in 2023, then rose by 14.72% to $1.0 billion in 2024, then gained by 11.85% to $1.2 billion in 2025, then fell by 6.35% to $1.1 billion in 2026.
• Per Business Quant, the three latest ONC Operating Expenses figures stand at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025).

Peer Comparison